Search This Blog

Thursday, May 2, 2019

Bluebird Bio reports Q1 EPS ($2.99) , consensus ($2.80)

Reports Q1 revenue $12.5M, consensus $13.24M. Cash, cash equivalents and marketable securities as of March 31, 2019 and December 31, 2018 were $1.73 billion and $1.89 billion, respectively. The decrease in cash, cash equivalents and marketable securities is primarily related to cash used in support of normal operating activities and cash used to purchase property, plant and equipment as the company continues the buildout of its manufacturing facility in Durham, North Carolina.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.